7777.T 3-D Matrix (JPX) -26.17% to JPY 567.00 at close 13 Mar 2026: risks remain

7777.T stock plunged 26.17% to JPY 567.00 at market close on 13 Mar 2026, driven by heavy trading and a wide intraday range. Volume surged to 23,134,000 shares versus a 50-day average of 8,092,505, amplifying the move. We see valuation and earnings signals that explain the sell‑off for 3-D Matrix, Ltd. (7777.T) on the JPX in Japan, and we outline short-term risks and realistic targets for traders and investors.

7777.T stock price action and drivers

Price fell from an open of JPY 637.00 to a day low of JPY 567.00. The one-day change was -201.00 JPY or -26.17% versus the previous close of JPY 768.00. Trading volume was 23,134,000 shares, 2.86 times the average volume. This combination indicates forced selling and stop-triggered orders. We link higher volume to increased volatility and rebalancing flows in the healthcare small-cap space. source

7777.T stock valuation vs healthcare peers

3-D Matrix shows stretched valuation ratios relative to the Healthcare sector. Price-to-sales is 10.18 and price-to-book is 21.24. The wider Healthcare peer average P/E is about 23.64. The company reports EPS of -3.30, producing a negative trailing PE of -217.27. These metrics make the stock sensitive to sentiment shifts and earnings updates. Investors prefer firms with stable earnings in this sector, which increases downside risk for 7777.T stock.

Technical signals and Meyka grade for 7777.T stock

Technical momentum turned sharply on the sell-off, but some indicators remain constructive. RSI sits at 62.56 and MACD shows a positive histogram of 7.32, suggesting short-term mean reversion potential. ADX at 48.01 signals a strong trending day. Meyka AI rates 7777.T with a score out of 100: 75.01 (Grade B+, Suggestion: BUY). This grade factors S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are model outputs and not investment advice.

Earnings, catalysts and risks for 7777.T stock

Next earnings date is scheduled for 11 Jun 2026. The company develops PuraMatrix hydrogel in regenerative medicine. Recent financial growth shows revenue up 51.11% year over year but operating income volatility persists. Key risks include volatile R&D outcomes, slow commercial adoption, and stretched valuation. We flag EPS weakness and interest coverage at -5.73 as near-term concerns. Positive catalysts would be clearer adoption data or partnerships.

Trading outlook and 7777.T stock forecast

Short-term traders face heightened volatility after the drop. Support sits near the intraday low JPY 567.00 and the 50-day average JPY 498.86. Resistance appears at JPY 631.50 (Bollinger middle). Meyka AI’s forecast model projects a monthly price of JPY 574.77 and a yearly level of JPY 214.86. The monthly projection implies minimal upside from here. Forecasts are model-based projections and not guarantees. We recommend position sizing and stop management for active traders. source

Final Thoughts

The 7777.T stock drop to JPY 567.00 reflects a liquidity-driven sell-off on top of stretched valuation metrics. We see a mix of short-term technical support and longer-term fundamental uncertainty given negative EPS (-3.30) and high price-to-book (21.24). Meyka AI’s forecast model projects a near-term monthly price of JPY 574.77, implying roughly +1.36% versus the close, and a yearly model target of JPY 214.86, implying -62.09% from JPY 567.00. Those divergent signals underscore a bifurcated outcome: short-term stabilization is possible, while downside remains if clinical or adoption news disappoints. We present a realistic price target range for risk management: near-term resistance JPY 630.00 and conservative medium-term target JPY 214.86. Forecasts are model-based projections and not guarantees. Meyka AI provides this analysis as an AI-powered market analysis platform and not as financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.